Clinical trials: Colon Cancer Liver Metastases
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Pulmonary Coin Lesion, Colon Cancer Liver Metastasis
Optical Detection of Malignancy During Percutaneous Interventions
Investigation of application possibilities of optical spectroscopy within the field of oncology. Optical spectroscopy enables the possibility to specifically differentiate between different (human) tissues.
- Conditions
- Pulmonary Coin Lesion, Colon Cancer Liver Metastasis, Breast Cancer
- Trial name
- NCT01730365
- Testing
- Core biopsy procedure
- Where
- Netherlands
- Volunteers
- 104 people
- Sponsor
- Philips Healthcare
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Colorectal Neoplasms, Neoplasm Metastasis
Health Economic Evaluation of Primovist-enhanced Liver MRI
Patients with a history of colorectal cancer and known or suspected liver metastases who are scheduled for contrast-enhanced tomographic imaging will be included in this study.
- Trial name
- NCT00764621
- Testing
- Primovist MRI, Extracellular contrast media (ECCM) MRI, Contrast-enhanced CT
- Where
- 44 sites in Austria, Germany and 7 more
- Volunteers
- 360 people
- Sponsor
- Bayer
Colorectal Cancer
A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
This open-label, single arm, multicenter study evaluated the resection rate in participants with colorectal cancer and previously untreated unresectable liver-only metastases after adding bevacizumab to 5-FU based doublet…
- Trial name
- NCT01695772
- Testing
- 5-FU based doublet chemotherapy, bevacizumab
- Where
- 7 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Cancer
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients with advanced and/or metastatic solid tumors for whom there there is no available therapy to provide clinical benefit or for those who have…
- Trial name
- NCT01832857
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Cornerstone Pharmaceuticals
Metastatic Colorectal Cancer
Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer
The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the neoadjuvant treatment (i.e. the Irinotecan Bead is administered prior to surgery) of resectable liver metastases from colorectal cancer.
- Trial name
- PARAGON-II (NCT00844233)
- Testing
- Irinotecan Bead
- Where
- 5 sites in Austria, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Colorectal Cancer, Liver Metastases
Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project
Investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver metastases in the USA.
- Trial name
- MORE (NCT01815879)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Andrew Kennedy
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Colorectal Cancer
An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases
This observational study will evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.
- Trial name
- PICASSO (NCT01343901)
- Testing
- Bevacizumab
- Where
- 126 sites in France
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Colorectal Liver Metastases
CyberKnife® for Hepatic Metastases From Colorectal Cancer
This prospective, multicenter study is intended to establish the efficacy and toxicity of treating unresectable colorectal liver metastases with accurately administered radiation using the CyberKnife stereotactic radiosurgery…
- Trial name
- NCT01318447
- Testing
- CyberKnife SBRT
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Accuray Incorporated
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.